Singular Genomics https://www.singulargenomics.com/ The company, known for its next-generation sequencing technologies such as the G4® Sequencing Platform and the upcoming G4XTM Spatial Sequencer, is now focused on further innovation in genomic and spatial multiomics research. Singular Genomics Systems, Inc. is a life science technology company founded in 2016 that develops next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians in advancing science and medicine. The company's mission centers on leveraging its proprietary Sequencing Engine platform, which underpins its core product tenets of accuracy, speed, flexibility, and scale. Its commercially available G4 Sequencing Platform is a benchtop genomic sequencer designed for fast and accurate results, while the G4X Spatial Sequencer, an upgrade to the G4 platform, enables high-throughput in situ direct sequencing of RNA, targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. The company is also developing the PX Integrated Solution, a multiomics platform that combines single-cell analysis, spatial analysis, genomics, and proteomics in one instrument. As of February 21, 2025, Singular Genomics was taken private following the closing of an acquisition by Deerfield Management. The company is headquartered in San Diego, California, with additional operations in La Jolla. Target CEO: Drew Spaventa https://www.linkedin.com/in/drew-spaventa-98087213/ Josh Stahl https://www.linkedin.com/in/joshua-stahl-77238627/ Target Owner: James E. Flynn https://www.linkedin.com/in/james-flynn-99304a72/ Deerfield Management Company, L.P. Singular Genomics is currently owned by Deerfield Management Company, L.P., following the completion of its acquisition on February 21, 2025. The transaction involved an affili